%PDF-1.6
%
1 0 obj
<>stream
doi:10.1371/journal.ppat.1009965
Jaryd R. Sullivan, Andréanne Lupien, Elias Kalthoff, Claire Hamela, Lorne Taylor, Kim A. Munro, T. Martin Schmeing, Laurent Kremer, Marcel A. Behr
Efficacy of epetraborole against Mycobacterium abscessus is increased with norvaline
10.1371/journal.ppat.1009965
http://dx.doi.org/10.1371/journal.ppat.1009965
2021-10-12
false
10.1371/journal.ppat.1009965
www.plospathogens.org
10.1371/journal.ppat.1009965
2021-10-12
false
www.plospathogens.org
endstream
endobj
2 0 obj
<>
endobj
5 0 obj
<>/ProcSet 14 0 R/XObject<>>>
endobj
6 0 obj
[17 0 R 18 0 R 19 0 R 20 0 R 21 0 R 22 0 R 23 0 R 24 0 R 25 0 R 26 0 R 27 0 R 28 0 R 29 0 R 30 0 R 31 0 R 32 0 R 33 0 R]
endobj
17 0 obj
<>/Border[0 0 0]>>
endobj
18 0 obj
<>/Border[0 0 0]>>
endobj
19 0 obj
<>/Border[0 0 0]>>
endobj
20 0 obj
<>/Border[0 0 0]>>
endobj
21 0 obj
<>/Border[0 0 0]>>
endobj
22 0 obj
<>/Border[0 0 0]>>
endobj
23 0 obj
<>/Border[0 0 0]>>
endobj
24 0 obj
<>/Border[0 0 0]>>
endobj
25 0 obj
<>/Border[0 0 0]>>
endobj
26 0 obj
<>/Border[0 0 0]>>
endobj
27 0 obj
<>/Border[0 0 0]>>
endobj
28 0 obj
<>/Border[0 0 0]>>
endobj
29 0 obj
<>/Border[0 0 0]>>
endobj
30 0 obj
<>/Border[0 0 0]>>
endobj
31 0 obj
<>/Border[0 0 0]>>
endobj
34 0 obj
<>
endobj
32 0 obj
<>/Border[0 0 0]>>
endobj
35 0 obj
<>
endobj
33 0 obj
<>/Border[0 0 0]>>
endobj
36 0 obj
<>
endobj
3 0 obj
<>stream
q
Q
q
12.0189 54.5953 583.087 707.414 re
W* n
q
1 0 0 1 12.0189 54.5953 cm
q
/I0 Do
Q
Q
Q
q
0 0 612 792 re
W* n
0.955 g
0.0001 w
200 707.4 m
576 707.4 l
576 481.401 l
200 481.401 l
f*
0.83 0.64 0.02 0 k
435.628 406.942 m
440.391 406.942 l
h
f*
454.847 380.92 m
459.609 380.92 l
h
f*
461.877 380.92 m
466.639 380.92 l
h
f*
438.86 354.898 m
443.622 354.898 l
h
f*
445.833 354.898 m
450.595 354.898 l
h
f*
312.661 328.932 m
317.424 328.932 l
h
f*
380.296 315.95 m
385.058 315.95 l
h
f*
448.214 315.95 m
452.92 315.95 l
h
f*
203.414 289.928 m
208.176 289.928 l
h
f*
210.387 289.928 m
219.912 289.928 l
h
f*
524.75 263.906 m
534.274 263.906 l
h
f*
536.542 263.906 m
546.066 263.906 l
h
f*
334.715 185.896 m
344.239 185.896 l
h
f*
346.45 185.896 m
355.975 185.896 l
h
f*
0 g
1 j
1 J
11.9999 0 0 11.9999 209.99 689.386 cm
BT
/F0 1 Tf
-0.0033 Tc
1 TL
0 0 Td
(Author)Tj
3.137 0 Td
(summary)Tj
ET
Q
q
1 j
1 J
0.0001 w
10 0 0 10 209.99 671.414 cm
BT
/F7 1 Tf
-0.004 Tc
1 TL
0 0 Td
(Current)Tj
3.4242 0 Td
(antimycobacterial)Tj
7.3814 0 Td
(drugs)Tj
2.4717 0 Td
(are)Tj
1.4457 0 Td
(inadequate)Tj
4.6148 0 Td
(to)Tj
1.0204 0 Td
(handle)Tj
2.9311 0 Td
(the)Tj
1.4683 0 Td
(increasing)Tj
4.3313 0 Td
(number)Tj
3.4186 0 Td
(of)Tj
1.0148 0 Td
(non-)Tj
-33.5223 -1.3039 Td
(tuberculous)Tj
4.9435 0 Td
(mycobacteria)Tj
5.5843 0 Td
(infections)Tj
4.1499 0 Td
(that)Tj
1.7801 0 Td
(eclipse)Tj
2.88 0 Td
(tuberculosis)Tj
5.0399 0 Td
(infections)Tj
4.1556 0 Td
(in)Tj
1.0318 0 Td
(many)Tj
2.4775 0 Td
(devel-)Tj
-32.0426 -1.2982 Td
(oped)Tj
2.194 0 Td
(countries.)Tj
4.1782 0 Td
(Of)Tj
1.2529 0 Td
(particular)Tj
4.1102 0 Td
(importance)Tj
4.8302 0 Td
(for)Tj
1.3833 0 Td
(cystic)Tj
2.4491 0 Td
(fibrosis)Tj
3.1521 0 Td
(patients,)Tj
/F13 1 Tf
3.5943 0 Td
( \n)Tj
-27.1443 -1.2983 Td
(\r\r\r\r)Tj
/F7 1 Tf
3.8154 0 Td
(is)Tj
0.8447 0 Td
(notoriously)Tj
4.8075 0 Td
(difficult)Tj
3.3505 0 Td
(to)Tj
1.0205 0 Td
(treat)Tj
2.0353 0 Td
(where)Tj
2.6475 0 Td
(patients)Tj
3.3619 0 Td
(spend)Tj
2.5908 0 Td
(extended)Tj
3.8495 0 Td
(time)Tj
2.0239 0 Td
(on)Tj
1.2699 0 Td
(antibiotics)Tj
-31.6174 -1.2983 Td
(with)Tj
1.9955 0 Td
(cure)Tj
1.9673 0 Td
(rates)Tj
2.1089 0 Td
(comparable)Tj
4.9039 0 Td
(to)Tj
1.0262 0 Td
(extreme)Tj
3.4469 0 Td
(drug)Tj
2.1089 0 Td
(resistant)Tj
/F13 1 Tf
3.583 0 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
1.3153 0 Td
( \r\n\r)Tj
/F7 1 Tf
(.)Tj
5.074 0 Td
(Here,)Tj
2.4321 0 Td
(we)Tj
1.3266 0 Td
(identified)Tj
-31.2886 -1.3039 Td
(epetraborole)Tj
5.2497 0 Td
(\(EPT\))Tj
2.6419 0 Td
(with)Tj
/F13 1 Tf
1.9955 0 Td
(\n)Tj
1.0148 0 Td
(\n )Tj
/F7 1 Tf
2.0636 0 Td
(and)Tj
/F13 1 Tf
1.7348 0 Td
(\n)Tj
1.0148 0 Td
(\n)Tj
/F7 1 Tf
1.8425 0 Td
(activities)Tj
3.7134 0 Td
(against)Tj
/F13 1 Tf
3.0274 0 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
1.3152 0 Td
(\r\r\r\r)Tj
/F7 1 Tf
(.)Tj
4.0536 0 Td
(We)Tj
1.6044 0 Td
(showed)Tj
-31.2716 -1.2982 Td
(that)Tj
1.7801 0 Td
(EPT)Tj
1.9616 0 Td
(targets)Tj
2.8686 0 Td
(the)Tj
1.4683 0 Td
(editing)Tj
3.0218 0 Td
(domain)Tj
3.3221 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4684 0 Td
(leucyl-tRNA)Tj
5.2327 0 Td
(synthetase)Tj
4.354 0 Td
(\(LeuRS\))Tj
3.4866 0 Td
(and)Tj
1.7291 0 Td
(that)Tj
-31.7081 -1.2983 Td
(escape)Tj
2.8062 0 Td
(mutants)Tj
3.5036 0 Td
(lost)Tj
1.6328 0 Td
(LeuRS)Tj
2.8063 0 Td
(editing)Tj
3.0217 0 Td
(activity,)Tj
3.3392 0 Td
(making)Tj
3.2541 0 Td
(these)Tj
2.2507 0 Td
(mutants)Tj
3.5093 0 Td
(susceptible)Tj
4.5751 0 Td
(to)Tj
1.0261 0 Td
(misami-)Tj
-31.7251 -1.3039 Td
(noacylation)Tj
4.8925 0 Td
(with)Tj
1.9956 0 Td
(leucine)Tj
3.0784 0 Td
(mimics.)Tj
3.4016 0 Td
(Most)Tj
2.279 0 Td
(importantly,)Tj
5.21 0 Td
(combination)Tj
5.3461 0 Td
(therapy)Tj
3.2485 0 Td
(of)Tj
1.0148 0 Td
(EPT)Tj
1.9616 0 Td
(and)Tj
-32.4281 -1.2983 Td
(norvaline)Tj
4.0195 0 Td
(limited)Tj
3.0727 0 Td
(the)Tj
1.4683 0 Td
(rate)Tj
1.7462 0 Td
(of)Tj
1.0148 0 Td
(EPT)Tj
1.9615 0 Td
(resistance)Tj
4.1329 0 Td
(in)Tj
1.0318 0 Td
(both)Tj
/F13 1 Tf
2.0636 0 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
1.3153 0 Td
(\r\r\r\r)Tj
/F7 1 Tf
3.8267 0 Td
(and)Tj
/F13 1 Tf
1.7292 0 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
1.3152 0 Td
( \r\n\r)Tj
/F7 1 Tf
(,)Tj
5.0683 0 Td
(and)Tj
-33.766 -1.2983 Td
(this)Tj
1.6724 0 Td
(was)Tj
1.7008 0 Td
(the)Tj
1.4683 0 Td
(first)Tj
1.8085 0 Td
(study)Tj
2.3867 0 Td
(to)Tj
1.0262 0 Td
(demonstrate)Tj
5.2327 0 Td
(improved)Tj
/F13 1 Tf
4.1102 0 Td
(\n)Tj
1.0148 0 Td
(\n)Tj
/F7 1 Tf
1.8425 0 Td
(efficacy)Tj
3.2202 0 Td
(of)Tj
1.0148 0 Td
(EPT)Tj
1.9615 0 Td
(and)Tj
1.7291 0 Td
(norvaline)Tj
-30.1887 -1.3039 Td
(compared)Tj
4.2462 0 Td
(to)Tj
1.0262 0 Td
(EPT)Tj
1.9559 0 Td
(in)Tj
1.0374 0 Td
(a)Tj
0.652 0 Td
(murine)Tj
3.1804 0 Td
(model)Tj
2.744 0 Td
(of)Tj
/F13 1 Tf
1.0148 0 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
1.3152 0 Td
(\r\r\r\r)Tj
/F7 1 Tf
3.8268 0 Td
(pulmonary)Tj
4.6431 0 Td
(infection.)Tj
4.0195 0 Td
(The)Tj
1.7801 0 Td
(demon-)Tj
-31.4416 -1.2982 Td
(stration)Tj
3.3051 0 Td
(of)Tj
1.0148 0 Td
(norvaline)Tj
4.0195 0 Td
(adjunct)Tj
3.2372 0 Td
(therapy)Tj
3.2485 0 Td
(with)Tj
1.9955 0 Td
(EPT)Tj
1.9616 0 Td
(for)Tj
/F13 1 Tf
1.389 0 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
1.3152 0 Td
(\r\r\r\r)Tj
/F7 1 Tf
3.8211 0 Td
(infections)Tj
4.1556 0 Td
(is)Tj
0.8447 0 Td
(promising)Tj
-30.3078 -1.2983 Td
(for)Tj
1.3889 0 Td
(cystic)Tj
2.4491 0 Td
(fibrosis)Tj
3.1465 0 Td
(patients)Tj
3.3675 0 Td
(and)Tj
1.7291 0 Td
(could)Tj
2.4548 0 Td
(translate)Tj
3.634 0 Td
(to)Tj
1.0261 0 Td
(other)Tj
2.3471 0 Td
(mycobacterial)Tj
5.828 0 Td
(infections,)Tj
4.3824 0 Td
(such)Tj
2.0579 0 Td
(as)Tj
-33.8114 -1.3039 Td
(tuberculosis.)Tj
ET
Q
q
1 j
1 J
0.0001 w
11.9999 0 0 11.9999 200.012 438.009 cm
BT
/F3 1 Tf
-0.0033 Tc
1 TL
0 0 Td
(Introduction)Tj
ET
Q
q
1 j
1 J
0.0001 w
10 0 0 10 200.012 421.002 cm
BT
/F13 1 Tf
-0.004 Tc
1 TL
0 0 Td
( \n)Tj
6.3609 0 Td
(\r\r\r\r)Tj
/F7 1 Tf
3.821 0 Td
(is)Tj
0.8504 0 Td
(a)Tj
0.652 0 Td
(nontuberculous)Tj
6.548 0 Td
(mycobacterium)Tj
6.4969 0 Td
(that)Tj
1.7745 0 Td
(commonly)Tj
4.5468 0 Td
(causes)Tj
2.7496 0 Td
(chronic)Tj
-33.8001 -1.2982 Td
(lung)Tj
2.0069 0 Td
(disease,)Tj
3.2428 0 Td
(especially)Tj
4.0195 0 Td
(among)Tj
2.9933 0 Td
(patients)Tj
3.3676 0 Td
(with)Tj
1.9956 0 Td
(cystic)Tj
2.4491 0 Td
(fibrosis)Tj
3.1464 0 Td
([)Tj
0.83 0.64 0.02 0 k
(1)Tj
0 g
(].)Tj
1.6044 0 Td
(Treatment)Tj
4.4447 0 Td
(of)Tj
1.0148 0 Td
(pulmonary)Tj
-30.2851 -1.3039 Td
(exacerbation)Tj
5.3234 0 Td
(relies)Tj
2.313 0 Td
(on)Tj
1.2756 0 Td
(a)Tj
0.652 0 Td
(regimen)Tj
3.5376 0 Td
(of)Tj
1.0148 0 Td
(intravenous)Tj
4.9606 0 Td
(amikacin)Tj
3.9118 0 Td
(\(AMK\),)Tj
3.3789 0 Td
(tigecycline,)Tj
4.6828 0 Td
(and)Tj
1.7291 0 Td
(imipenem)Tj
-32.7796 -1.2983 Td
(plus)Tj
1.8708 0 Td
(an)Tj
1.2019 0 Td
(oral)Tj
1.7801 0 Td
(macrolide)Tj
4.2406 0 Td
(if)Tj
0.7711 0 Td
(the)Tj
1.474 0 Td
(isolate)Tj
2.7552 0 Td
(is)Tj
0.8504 0 Td
(susceptible)Tj
4.5751 0 Td
(to)Tj
1.0261 0 Td
(macrolides)Tj
4.5978 0 Td
([)Tj
0.83 0.64 0.02 0 k
(2)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
(3)Tj
0 g
(].)Tj
2.3017 0 Td
(Despite)Tj
3.2485 0 Td
(guideline-based)Tj
-30.6933 -1.2983 Td
(treatment,)Tj
4.3596 0 Td
(combination)Tj
5.3461 0 Td
(therapy)Tj
3.2485 0 Td
(typically)Tj
3.5603 0 Td
(results)Tj
2.8119 0 Td
(in)Tj
1.0375 0 Td
(cure)Tj
1.9616 0 Td
(rates)Tj
2.1089 0 Td
(of)Tj
1.0148 0 Td
(50%)Tj
1.9276 0 Td
(or)Tj
1.0998 0 Td
(less)Tj
1.6101 0 Td
(due)Tj
1.7008 0 Td
(to)Tj
1.0261 0 Td
(the)Tj
1.4683 0 Td
(bacte-)Tj
-34.2819 -1.3039 Td
(rium)Tj
2.2053 0 Td
(being)Tj
2.4321 0 Td
(intrinsically)Tj
4.9549 0 Td
(resistant)Tj
3.583 0 Td
(to)Tj
1.0205 0 Td
(many)Tj
2.4774 0 Td
(antibiotic)Tj
4.0422 0 Td
(classes)Tj
2.829 0 Td
([)Tj
0.83 0.64 0.02 0 k
(4)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
(5)Tj
0 g
(].)Tj
2.3017 0 Td
(Unfortunately,)Tj
6.1285 0 Td
(the)Tj
/F13 1 Tf
1.4683 0 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
1.3153 0 Td
(\r\r)Tj
-34.7582 -1.2982 Td
(\r\r)Tj
/F7 1 Tf
1.4116 0 Td
(drug-development)Tj
7.6535 0 Td
(pipeline)Tj
3.4299 0 Td
(is)Tj
0.8504 0 Td
(limited)Tj
3.067 0 Td
(to)Tj
1.0262 0 Td
(a)Tj
0.6576 0 Td
(handful)Tj
3.3165 0 Td
(of)Tj
1.0148 0 Td
(repurposed)Tj
4.7679 0 Td
(drugs)Tj
2.4718 0 Td
(\(clofazimine,)Tj
-29.6672 -1.2983 Td
(rifabutin,)Tj
3.9514 0 Td
(and)Tj
1.7291 0 Td
(bedaquiline\))Tj
5.2441 0 Td
([)Tj
0.83 0.64 0.02 0 k
(6)Tj
0 g
(].)Tj
1.5987 0 Td
(Lately,)Tj
2.8403 0 Td
(antibiotics)Tj
4.3994 0 Td
(that)Tj
1.7801 0 Td
(have)Tj
2.058 0 Td
(shown)Tj
2.8459 0 Td
(activity)Tj
3.1181 0 Td
(in)Tj
1.0375 0 Td
(pre-clinical)Tj
4.7395 0 Td
(stud-)Tj
-35.3421 -1.2983 Td
(ies)Tj
1.2642 0 Td
(include)Tj
3.1804 0 Td
(the)Tj
1.4627 0 Td
(oxazolidinones)Tj
6.2419 0 Td
(\(LCB01-0371)Tj
5.5388 0 Td
([)Tj
0.83 0.64 0.02 0 k
(7)Tj
0 g
(])Tj
1.372 0 Td
(and)Tj
1.7234 0 Td
(tedizolid)Tj
3.6964 0 Td
([)Tj
0.83 0.64 0.02 0 k
(8)Tj
0 g
(]\))Tj
1.7064 0 Td
(that)Tj
1.7745 0 Td
(target)Tj
2.5058 0 Td
(the)Tj
1.4684 0 Td
(50S)Tj
1.6384 0 Td
(ribosomal)Tj
-33.5733 -1.3039 Td
(subunit)Tj
3.2541 0 Td
(and)Tj
1.7348 0 Td
(PIPD1/indol-2-carboxamides)Tj
12.0302 0 Td
(that)Tj
1.7801 0 Td
(target)Tj
2.5115 0 Td
(the)Tj
1.4683 0 Td
(mycolic)Tj
3.3619 0 Td
(acid)Tj
1.8708 0 Td
(transporter)Tj
4.7225 0 Td
(MmpL3)Tj
-32.7342 -1.2983 Td
([)Tj
0.83 0.64 0.02 0 k
(9)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
(10)Tj
0 g
(].)Tj
1.1962 -1.2982 Td
(Recently,)Tj
3.8891 0 Td
(aminoacyl-tRNA)Tj
7.0469 0 Td
(synthetases)Tj
4.7111 0 Td
(\(aaRSs\))Tj
3.2258 0 Td
(became)Tj
3.2485 0 Td
(targets)Tj
2.8743 0 Td
(of)Tj
1.0148 0 Td
(interest)Tj
3.2088 0 Td
(for)Tj
1.389 0 Td
(drug)Tj
2.1089 0 Td
(discov-)Tj
-33.9134 -1.3039 Td
(ery)Tj
1.4683 0 Td
(when)Tj
2.4038 0 Td
(benzoxaboroles)Tj
6.4402 0 Td
(were)Tj
2.126 0 Td
(identified)Tj
4.0535 0 Td
(as)Tj
1.0148 0 Td
(novel)Tj
2.4038 0 Td
(boron-based)Tj
5.261 0 Td
(pharmacophores)Tj
6.9619 0 Td
([)Tj
0.83 0.64 0.02 0 k
(11)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
(12)Tj
0 g
(].)Tj
-32.1333 -1.2983 Td
(aaRSs)Tj
2.5454 0 Td
(are)Tj
1.4457 0 Td
(enzymes)Tj
3.668 0 Td
(that)Tj
1.7745 0 Td
(aminoacylate)Tj
5.5105 0 Td
(tRNAs)Tj
2.9253 0 Td
(with)Tj
1.9956 0 Td
(their)Tj
2.109 0 Td
(cognate)Tj
3.3165 0 Td
(amino)Tj
2.8006 0 Td
(acids.)Tj
2.4548 0 Td
(All)Tj
1.4003 0 Td
(aaRSs)Tj
2.5455 0 Td
(have)Tj
2.0579 0 Td
(an)Tj
-36.5496 -1.2983 Td
(aminoacylation)Tj
6.4062 0 Td
(domain)Tj
3.3279 0 Td
(while)Tj
2.364 0 Td
(some)Tj
2.3358 0 Td
(are)Tj
1.4456 0 Td
(bifunctional)Tj
5.0854 0 Td
(and)Tj
1.7291 0 Td
(contain)Tj
3.2485 0 Td
(an)Tj
1.2018 0 Td
(editing)Tj
3.0161 0 Td
(domain.)Tj
3.5489 0 Td
(The)Tj
1.7859 0 Td
(ami-)Tj
-35.4952 -1.3039 Td
(noacylation)Tj
4.8868 0 Td
(domain)Tj
3.3222 0 Td
(forms)Tj
2.5682 0 Td
(an)Tj
1.2019 0 Td
(aminoacyl)Tj
4.354 0 Td
(adenylate)Tj
4.0138 0 Td
(through)Tj
3.4469 0 Td
(condensation)Tj
5.6126 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4683 0 Td
(amino)Tj
2.795 0 Td
(acid)Tj
-34.6845 -1.2982 Td
(with)Tj
1.9955 0 Td
(ATP,)Tj
2.3017 0 Td
(and)Tj
1.7292 0 Td
(then)Tj
2.0182 0 Td
(transfers)Tj
3.6794 0 Td
(the)Tj
1.4683 0 Td
(aminoacyl)Tj
4.354 0 Td
(moiety)Tj
2.9877 0 Td
(to)Tj
1.0261 0 Td
(the)Tj
1.4684 0 Td
(3')Tj
0.9127 0 Td
(terminal)Tj
3.6283 0 Td
(adenosine)Tj
4.2633 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4684 0 Td
(tRNA)Tj
-34.316 -1.2983 Td
(acceptor)Tj
3.6169 0 Td
(stem.)Tj
2.3471 0 Td
(Some)Tj
2.4491 0 Td
(aaRSs,)Tj
2.7666 0 Td
(however,)Tj
3.8381 0 Td
(have)Tj
2.0636 0 Td
(evolved)Tj
3.2542 0 Td
(an)Tj
1.2019 0 Td
(editing)Tj
3.0217 0 Td
(domain)Tj
3.3221 0 Td
(to)Tj
1.0262 0 Td
(ensure)Tj
2.8743 0 Td
(the)Tj
1.4683 0 Td
(correct)Tj
-33.2501 -1.3039 Td
(amino)Tj
2.7949 0 Td
(acid)Tj
1.8708 0 Td
(is)Tj
0.8504 0 Td
(ligated)Tj
2.88 0 Td
(to)Tj
1.0262 0 Td
(its)Tj
1.1451 0 Td
(tRNA)Tj
2.5625 0 Td
([)Tj
0.83 0.64 0.02 0 k
(13)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
(14)Tj
0 g
(].)Tj
3.2542 0 Td
(This)Tj
1.9842 0 Td
(domain)Tj
3.3279 0 Td
(is)Tj
0.8447 0 Td
(critical)Tj
2.9537 0 Td
(for)Tj
1.3833 0 Td
(aaRSs)Tj
2.5455 0 Td
(that)Tj
1.7801 0 Td
(must)Tj
2.2281 0 Td
(distin-)Tj
-33.4316 -1.2983 Td
(guish)Tj
2.3697 0 Td
(their)Tj
2.1033 0 Td
(cognate)Tj
3.3222 0 Td
(amino)Tj
2.7949 0 Td
(acid)Tj
1.8765 0 Td
(from)Tj
2.2054 0 Td
(structurally)Tj
4.7792 0 Td
(similar)Tj
2.9877 0 Td
(amino)Tj
2.7949 0 Td
(acids)Tj
2.2337 0 Td
(like)Tj
1.6497 0 Td
(branched-chain)Tj
-29.1172 -1.2983 Td
(amino)Tj
2.7949 0 Td
(acids.)Tj
2.4604 0 Td
(Leucyl-tRNA)Tj
5.5219 0 Td
(synthetases)Tj
4.7112 0 Td
(\(LeuRSs\))Tj
3.8494 0 Td
(are)Tj
1.4456 0 Td
(examples)Tj
3.9118 0 Td
(of)Tj
1.0148 0 Td
(aaRSs)Tj
2.5455 0 Td
(that)Tj
1.7802 0 Td
(rely)Tj
1.7178 0 Td
(on)Tj
1.2755 0 Td
(their)Tj
2.109 0 Td
(edit-)Tj
-35.138 -1.2982 Td
(ing)Tj
1.5023 0 Td
(domains)Tj
3.6793 0 Td
(to)Tj
1.0262 0 Td
(limit)Tj
2.1203 0 Td
(misaminoacylation)Tj
7.8576 0 Td
(of)Tj
1.0148 0 Td
(tRNA)Tj
2.5625 0 Td
(with)Tj
1.9956 0 Td
(near-cognate)Tj
5.4481 0 Td
(amino)Tj
2.795 0 Td
(acids)Tj
2.2336 0 Td
(and)Tj
1.7292 0 Td
(maintain)Tj
-33.9645 -1.3039 Td
(the)Tj
1.4683 0 Td
(fidelity)Tj
2.9934 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4683 0 Td
(genetic)Tj
3.0727 0 Td
(code.)Tj
-8.8213 -1.2983 Td
(Herein,)Tj
3.2484 0 Td
(we)Tj
1.3267 0 Td
(identified)Tj
4.0591 0 Td
(epetraborole)Tj
5.2498 0 Td
(\(EPT\))Tj
2.6418 0 Td
(from)Tj
2.2054 0 Td
(the)Tj
1.4683 0 Td
(Medicines)Tj
4.354 0 Td
(for)Tj
1.389 0 Td
(Malaria)Tj
3.2995 0 Td
(Venture)Tj
3.5036 0 Td
(\(MMV\))Tj
-33.9418 -1.2983 Td
(Open)Tj
2.4547 0 Td
(pandemic)Tj
4.1839 0 Td
(response)Tj
3.7304 0 Td
(box)Tj
1.7008 0 Td
(as)Tj
1.0148 0 Td
(a)Tj
0.652 0 Td
(LeuRS)Tj
2.8062 0 Td
(inhibitor)Tj
3.7814 0 Td
(in)Tj
/F13 1 Tf
1.0375 0 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
1.3153 0 Td
(\r\r\r\r)Tj
/F7 1 Tf
3.8211 0 Td
(with)Tj
2.0012 0 Td
(nanomolar)Tj
4.6374 0 Td
(activity)Tj
/F13 1 Tf
3.1181 0 Td
(\n)Tj
-36.2548 -1.3039 Td
(\n )Tj
/F7 1 Tf
2.0636 0 Td
(and)Tj
1.7291 0 Td
(activity)Tj
3.1181 0 Td
(in)Tj
1.0374 0 Td
(zebrafish)Tj
3.8098 0 Td
(embryos)Tj
3.6623 0 Td
(and)Tj
1.7291 0 Td
(NOD.SCID)Tj
4.8813 0 Td
(mice.)Tj
2.3811 0 Td
(Interestingly,)Tj
5.4935 0 Td
(EPT)Tj
1.9559 0 Td
(was)Tj
1.7007 0 Td
(more)Tj
-33.5619 -1.2983 Td
(active)Tj
2.5171 0 Td
(against)Tj
/F13 1 Tf
3.0331 0 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
1.3152 0 Td
(\r\r\r\r)Tj
/F7 1 Tf
3.8211 0 Td
(than)Tj
/F13 1 Tf
2.0296 0 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
1.3209 0 Td
( \r\n\r)Tj
/F7 1 Tf
(,)Tj
5.0683 0 Td
(and)Tj
1.7292 0 Td
(this)Tj
1.6724 0 Td
(observation)Tj
4.9039 0 Td
(was)Tj
1.6951 0 Td
(not)Tj
1.5761 0 Td
(supported)Tj
4.2689 0 Td
(by)Tj
ET
Q
q
1 j
1 J
0.0001 w
576 737.1 m
36 737.1 l
36 737.6 l
576 737.6 l
f*
Q
q
34.9795 742.734 100.29 12.3591 re
W* n
q
1 0 0 1 34.9795 742.734 cm
q
/I5 Do
Q
Q
Q
q
0 0 612 792 re
W* n
1 j
1 J
0.0001 w
7.9999 0 0 7.9999 420.831 745.795 cm
BT
/F0 1 Tf
-0.005 Tc
1 TL
0 0 Td
(Epetrabor)Tj
4.3157 0 Td
(ole)Tj
1.5237 0 Td
(plus)Tj
2.0197 0 Td
(norvaline)Tj
4.1953 0 Td
(for)Tj
/F6 1 Tf
1.3677 0 Td
(M)Tj
/F0 1 Tf
(.)Tj
/F6 1 Tf
1.3181 0 Td
(abscessus)Tj
ET
Q
q
1 j
1 J
0.0001 w
36 48.0002 m
576 48.0002 l
576 47.5002 l
36 47.5002 l
f*
0.83 0.64 0.02 0 k
102.047 34.9228 m
256.195 34.9228 l
h
f*
0 g
7.9999 0 0 7.9999 36 36 cm
BT
/F0 1 Tf
-0.005 Tc
1 TL
0 0 Td
(PLOS)Tj
2.8559 0 Td
(Pathogens)Tj
4.9252 0 Td
(|)Tj
0.83 0.64 0.02 0 k
0.4748 0 Td
(https://)Tj
2.9552 0 Td
(doi.org/10.13)Tj
5.7331 0 Td
(71/journal.p)Tj
5.1236 0 Td
(pat.1009)Tj
3.8198 0 Td
(965)Tj
0 g
2.6362 0 Td
(October)Tj
3.7276 0 Td
(12,)Tj
1.5874 0 Td
(2021)Tj
31.3018 0 Td
(2)Tj
0.7654 0 Td
(/)Tj
0.496 0 Td
(28)Tj
ET
Q
q
0.83 0.64 0.02 0 k
1 j
1 J
0.0001 w
85.8898 685.644 m
186.746 685.644 l
h
f*
36 674.646 m
40.1953 674.646 l
h
f*
0 g
7.9999 0 0 7.9999 36 708.718 cm
BT
/F10 1 Tf
-0.025 Tc
1 TL
0 0 Td
(data)Tj
1.7929 0 Td
(has)Tj
1.5378 0 Td
(been)Tj
2.0055 0 Td
(deposited)Tj
3.8268 0 Td
(in)Tj
0.8858 0 Td
(the)Tj
1.3749 0 Td
(NCBI)Tj
2.1118 0 Td
(Sequence)Tj
-13.5355 -1.3748 Td
(Read)Tj
2.126 0 Td
(Archive)Tj
2.9834 0 Td
(under)Tj
2.367 0 Td
(the)Tj
1.3677 0 Td
(NCBI)Tj
2.1189 0 Td
(BioProjec)Tj
3.5292 0 Td
(t)Tj
0.4748 0 Td
(ID)Tj
-14.967 -1.3748 Td
(PRJNA756101)Tj
5.485 0 Td
(.)Tj
0.4465 0 Td
(\()Tj
0.83 0.64 0.02 0 k
(https://www)Tj
4.8402 0 Td
(.ncbi.nlm.n)Tj
4.1244 0 Td
(ih.gov/sra/)Tj
-14.8961 -1.3748 Td
(X)Tj
0 g
(\).)Tj
/F9 1 Tf
0 -2.126 Td
(Funding:)Tj
/F10 1 Tf
3.5716 0 Td
(This)Tj
1.7788 0 Td
(work)Tj
2.0622 0 Td
(was)Tj
1.7008 0 Td
(funded)Tj
2.7922 0 Td
(by)Tj
1.1196 0 Td
(Cystic)Tj
2.452 0 Td
(Fibrosis)Tj
-15.4772 -1.3748 Td
(Canada)Tj
2.9551 0 Td
(\(to)Tj
1.2543 0 Td
(J.R.S.)Tj
2.4308 0 Td
(and)Tj
1.5874 0 Td
(M.A.B.\),)Tj
3.2315 0 Td
(the)Tj
1.3677 0 Td
(Research)Tj
-12.8268 -1.3748 Td
(Institute)Tj
3.2244 0 Td
(of)Tj
0.9496 0 Td
(the)Tj
1.3677 0 Td
(McGill)Tj
2.5654 0 Td
(Univers)Tj
2.8205 0 Td
(ity)Tj
1.0913 0 Td
(Health)Tj
2.5725 0 Td
(Centre)Tj
2.6292 0 Td
(\(to)Tj
-17.2206 -1.3748 Td
(J.R.S.\),)Tj
2.9551 0 Td
(the)Tj
1.3748 0 Td
(Harrison)Tj
3.4016 0 Td
(Watson)Tj
3.0756 0 Td
(Fellowsh)Tj
3.2315 0 Td
(ip)Tj
0.8859 0 Td
(\(to)Tj
1.2614 0 Td
(J.R.S.\),)Tj
-16.1859 -1.3748 Td
(the)Tj
1.3677 0 Td
(Structure-guid)Tj
5.3646 0 Td
(ed)Tj
1.1126 0 Td
(Drug)Tj
2.0622 0 Td
(Discovery)Tj
3.8906 0 Td
(Coalition)Tj
3.4229 0 Td
(\(to)Tj
-17.2206 -1.3749 Td
(M.A.B.\),)Tj
3.2315 0 Td
(CIHR)Tj
2.1756 0 Td
(operating)Tj
3.7063 0 Td
(grant)Tj
2.1544 0 Td
(\(to)Tj
1.2543 0 Td
(M.A.B.\))Tj
3.0047 0 Td
(and)Tj
1.5875 0 Td
(was)Tj
-17.1143 -1.3748 Td
(supported)Tj
3.9897 0 Td
(by)Tj
1.1197 0 Td
(Vaincre)Tj
2.9835 0 Td
(la)Tj
0.8292 0 Td
(Mucoviscido)Tj
4.7197 0 Td
(se)Tj
-13.6418 -1.3748 Td
(\(RF2020050)Tj
4.6275 0 Td
(2678\))Tj
2.4237 0 Td
(\(to)Tj
1.2543 0 Td
(L.K\))Tj
1.7504 0 Td
(and)Tj
1.5874 0 Td
(the)Tj
1.3749 0 Td
(Association)Tj
-13.0182 -1.3748 Td
(Gregory)Tj
3.2102 0 Td
(Lemarchal)Tj
4.1103 0 Td
(\(to)Tj
1.2543 0 Td
(L.K\).)Tj
1.9772 0 Td
(The)Tj
1.5874 0 Td
(funders)Tj
3.0473 0 Td
(had)Tj
1.5874 0 Td
(no)Tj
-16.7741 -1.3748 Td
(role)Tj
1.6157 0 Td
(in)Tj
0.8858 0 Td
(study)Tj
2.2678 0 Td
(design,)Tj
2.8984 0 Td
(data)Tj
1.793 0 Td
(collection)Tj
3.7346 0 Td
(and)Tj
1.5874 0 Td
(analysis,)Tj
-14.7827 -1.3748 Td
(decision)Tj
3.2882 0 Td
(to)Tj
0.9496 0 Td
(publish,)Tj
3.1465 0 Td
(or)Tj
0.9992 0 Td
(preparation)Tj
4.4433 0 Td
(of)Tj
0.9496 0 Td
(the)Tj
-13.7764 -1.3748 Td
(manuscript.)Tj
/F9 1 Tf
0 -2.126 Td
(Competing)Tj
4.3795 0 Td
(interests)Tj
3.3307 0 Td
(:)Tj
/F10 1 Tf
0.4819 0 Td
(The)Tj
1.5875 0 Td
(authors)Tj
3.0401 0 Td
(have)Tj
1.963 0 Td
(declared)Tj
-14.7827 -1.3749 Td
(that)Tj
1.6228 0 Td
(no)Tj
1.1693 0 Td
(competing)Tj
4.1599 0 Td
(interests)Tj
3.3874 0 Td
(exist.)Tj
ET
Q
endstream
endobj
37 0 obj
<>
endobj
39 0 obj
<>/ProcSet 14 0 R/XObject<>>>
endobj
40 0 obj
[46 0 R 47 0 R 48 0 R 49 0 R 50 0 R 51 0 R 52 0 R 53 0 R 54 0 R 55 0 R 56 0 R 57 0 R 58 0 R 59 0 R 60 0 R]
endobj
46 0 obj
<>/Border[0 0 0]>>
endobj
47 0 obj
<>/Border[0 0 0]>>
endobj
48 0 obj
<>/Border[0 0 0]>>
endobj
49 0 obj
<>/Border[0 0 0]>>
endobj
50 0 obj
<>/Border[0 0 0]>>
endobj
51 0 obj
<>/Border[0 0 0]>>
endobj
52 0 obj
<>/Border[0 0 0]>>
endobj
53 0 obj
<>/Border[0 0 0]>>
endobj
54 0 obj
<>/Border[0 0 0]>>
endobj
55 0 obj
<>/Border[0 0 0]>>
endobj
56 0 obj
<>/Border[0 0 0]>>
endobj
57 0 obj
<>/Border[0 0 0]>>
endobj
58 0 obj
<>/Border[0 0 0]>>
endobj
59 0 obj
<>/Border[0 0 0]>>
endobj
60 0 obj
<>/Border[0 0 0]>>
endobj
61 0 obj
<>
endobj
38 0 obj
<>stream
q
Q
q
12.0189 54.5953 583.087 707.414 re
W* n
q
1 0 0 1 12.0189 54.5953 cm
q
/I0 Do
Q
Q
Q
q
0 0 612 792 re
W* n
0.83 0.64 0.02 0 k
535.975 523.899 m
545.499 523.899 l
h
f*
220.479 497.934 m
272.92 497.934 l
h
f*
230.4 484.894 m
282.047 484.894 l
h
f*
309.883 393.902 m
336.246 393.902 l
h
f*
306.142 380.92 m
335.339 380.92 l
h
f*
281.424 341.915 m
290.948 341.915 l
h
f*
203.414 289.928 m
237.317 289.928 l
h
f*
265.72 276.945 m
275.244 276.945 l
h
f*
405.921 276.945 m
415.446 276.945 l
h
f*
406.091 172.913 m
440.05 172.913 l
h
f*
401.159 133.909 m
435.061 133.909 l
h
f*
251.83 107.943 m
261.354 107.943 l
h
f*
457.342 81.9213 m
482.683 81.9213 l
h
f*
491.698 81.9213 m
501.222 81.9213 l
h
f*
0 g
1 j
1 J
0.0001 w
10 0 0 10 200.012 707.414 cm
BT
/F7 1 Tf
-0.004 Tc
1 TL
0 0 Td
(structural)Tj
4.0761 0 Td
(differences)Tj
4.5695 0 Td
(in)Tj
1.0318 0 Td
(the)Tj
1.474 0 Td
(crystal)Tj
2.8063 0 Td
(structures)Tj
4.1839 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4683 0 Td
(LeuRS)Tj
2.8063 0 Td
(editing)Tj
3.0217 0 Td
(domain)Tj
3.3222 0 Td
(of)Tj
/F13 1 Tf
1.0148 0 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
1.3152 0 Td
(\r\r\r\r)Tj
/F7 1 Tf
3.8268 0 Td
(and)Tj
/F13 1 Tf
-35.9317 -1.3039 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
1.3152 0 Td
( \r\n\r)Tj
/F7 1 Tf
4.8472 0 Td
(bound)Tj
2.8347 0 Td
(to)Tj
1.0261 0 Td
(EPT.)Tj
2.1883 0 Td
(Furthermore,)Tj
5.6126 0 Td
(we)Tj
1.3266 0 Td
(highlighted)Tj
4.7622 0 Td
(the)Tj
1.474 0 Td
(utility)Tj
2.5795 0 Td
(of)Tj
1.0148 0 Td
(norvaline)Tj
4.0195 0 Td
(to)Tj
1.0261 0 Td
(target)Tj
-34.0268 -1.2982 Td
(LeuRS)Tj
2.8062 0 Td
(editing)Tj
3.0161 0 Td
(deficient)Tj
3.6907 0 Td
(escape)Tj
2.8006 0 Td
(mutants)Tj
3.5092 0 Td
(and)Tj
1.7292 0 Td
(suppress)Tj
3.6566 0 Td
(resistance)Tj
/F13 1 Tf
4.1329 0 Td
(\n)Tj
1.0205 0 Td
(\n )Tj
/F7 1 Tf
2.0579 0 Td
(by)Tj
1.1849 0 Td
(misincorporation)Tj
-29.6048 -1.2983 Td
(of)Tj
1.0147 0 Td
(norvaline)Tj
4.0195 0 Td
(in)Tj
1.0375 0 Td
(place)Tj
2.2621 0 Td
(of)Tj
1.0148 0 Td
(leucine)Tj
3.0784 0 Td
(residues)Tj
3.4866 0 Td
(resulting)Tj
3.7303 0 Td
(in)Tj
1.0318 0 Td
(disrupted)Tj
4.0422 0 Td
(protein)Tj
3.1521 0 Td
(folding.)Tj
3.2995 0 Td
(Importantly,)Tj
5.2781 0 Td
(we)Tj
-36.4476 -1.2983 Td
(showed)Tj
3.2484 0 Td
(that)Tj
1.7802 0 Td
(EPT)Tj
1.9615 0 Td
(and)Tj
1.7292 0 Td
(norvaline)Tj
4.0195 0 Td
(combination)Tj
5.3461 0 Td
(has)Tj
1.542 0 Td
(improved)Tj
4.1102 0 Td
(efficacy)Tj
3.2202 0 Td
(over)Tj
1.9785 0 Td
(EPT)Tj
1.9616 0 Td
(monotherapy)Tj
5.6296 0 Td
(in)Tj
-36.527 -1.3039 Td
(a)Tj
0.6519 0 Td
(murine)Tj
3.1805 0 Td
(model)Tj
2.7439 0 Td
(of)Tj
/F13 1 Tf
1.0148 0 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
1.3153 0 Td
(\r\r\r\r)Tj
/F7 1 Tf
3.821 0 Td
(infection.)Tj
4.0195 0 Td
(These)Tj
2.5682 0 Td
(data)Tj
1.9105 0 Td
(support)Tj
3.3222 0 Td
(the)Tj
1.4684 0 Td
(potential)Tj
3.7587 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.474 0 Td
(benzoxabor-)Tj
-32.2637 -1.2982 Td
(ole)Tj
1.3946 0 Td
(scaffold)Tj
3.2938 0 Td
(in)Tj
1.0375 0 Td
(the)Tj
1.4683 0 Td
(antimycobacterial)Tj
7.3814 0 Td
(drug)Tj
2.109 0 Td
(pipeline)Tj
3.4299 0 Td
(and)Tj
1.7291 0 Td
(suggest)Tj
3.1238 0 Td
(that)Tj
1.7801 0 Td
(its)Tj
1.1452 0 Td
(activity)Tj
3.1181 0 Td
(can)Tj
1.6271 0 Td
(be)Tj
1.1508 0 Td
(potenti-)Tj
-33.7887 -1.2983 Td
(ated)Tj
1.9048 0 Td
(by)Tj
1.1792 0 Td
(supplementation)Tj
6.9562 0 Td
(with)Tj
2.0012 0 Td
(norvaline)Tj
4.0196 0 Td
(or)Tj
1.0998 0 Td
(a)Tj
0.652 0 Td
(norvaline)Tj
4.0195 0 Td
(derivative.)Tj
ET
Q
q
1 j
1 J
0.0001 w
11.9999 0 0 11.9999 200.012 572.995 cm
BT
/F3 1 Tf
-0.0033 Tc
1 TL
0 0 Td
(Results)Tj
/F14 1 Tf
0 -1.4976 Td
(Discovery)Tj
4.3512 0 Td
(of)Tj
1.0677 0 Td
(an)Tj
1.2425 0 Td
(antimycobacterial)Tj
7.7434 0 Td
(inhibitor)Tj
3.978 0 Td
(against)Tj
/F15 1 Tf
3.2031 0 Td
()Tj
/F14 1 Tf
(.)Tj
/F15 1 Tf
1.3465 0 Td
()Tj
ET
Q
q
1 j
1 J
0.0001 w
10 0 0 10 200.012 538.016 cm
BT
/F7 1 Tf
-0.004 Tc
1 TL
0 0 Td
(To)Tj
1.3379 0 Td
(identify)Tj
3.2938 0 Td
(compounds)Tj
4.9606 0 Td
(with)Tj
1.9956 0 Td
(antimycobacterial)Tj
7.3757 0 Td
(activity,)Tj
3.3449 0 Td
(we)Tj
1.3266 0 Td
(first)Tj
1.8085 0 Td
(engineered)Tj
4.6431 0 Td
(a)Tj
0.652 0 Td
(luminescent)Tj
/F13 1 Tf
5.108 0 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
-35.8467 -1.3039 Td
(\r\r\r\r)Tj
/F7 1 Tf
3.821 0 Td
(ATCC)Tj
2.8403 0 Td
(19977)Tj
2.6022 0 Td
(strain)Tj
2.5002 0 Td
(which)Tj
2.6475 0 Td
(constitutively)Tj
5.5956 0 Td
(expressed)Tj
4.0932 0 Td
(the)Tj
/F13 1 Tf
1.474 0 Td
()Tj
/F7 1 Tf
4.5864 0 Td
(operon)Tj
3.0954 0 Td
([)Tj
0.83 0.64 0.02 0 k
(15)Tj
0 g
(])Tj
1.8482 0 Td
(\()Tj
/F13 1 Tf
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
-35.104 -1.2982 Td
(\r\r\r\r)Tj
3.821 0 Td
()Tj
/F7 1 Tf
(\).)Tj
2.0296 0 Td
(We)Tj
1.6101 0 Td
(then)Tj
2.0182 0 Td
(screened)Tj
3.7191 0 Td
(the)Tj
1.474 0 Td
(176)Tj
1.6441 0 Td
(compound)Tj
4.5977 0 Td
(open-library)Tj
5.2214 0 Td
(provided)Tj
3.8154 0 Td
(by)Tj
1.1792 0 Td
(GlaxoSmithK-)Tj
-31.1298 -1.2983 Td
(line)Tj
1.7064 0 Td
(\()Tj
0.83 0.64 0.02 0 k
(S1AS1C)Tj
4.3256 0 Td
(Fig)Tj
0 g
(\))Tj
1.8199 0 Td
(and)Tj
1.7291 0 Td
(the)Tj
1.4683 0 Td
(400)Tj
1.6498 0 Td
(compound)Tj
4.5977 0 Td
(Pathogen)Tj
3.9855 0 Td
(and)Tj
1.7292 0 Td
(Pandemic)Tj
4.2236 0 Td
(Response)Tj
3.9798 0 Td
(Boxes)Tj
2.5568 0 Td
(from)Tj
-33.7717 -1.3039 Td
(MMV)Tj
2.6985 0 Td
(\()Tj
0.83 0.64 0.02 0 k
(S1DS1F)Tj
4.2463 0 Td
(Fig)Tj
0 g
(\))Tj
1.8198 0 Td
(using)Tj
2.3868 0 Td
(a)Tj
0.6519 0 Td
(threshold)Tj
/F16 1 Tf
0 Tc
4.0139 0 Td
()Tj
/F7 1 Tf
-0.004 Tc
0.9921 0 Td
(90%)Tj
1.9275 0 Td
(reduction)Tj
4.1159 0 Td
(in)Tj
1.0318 0 Td
(luminescence)Tj
5.6579 0 Td
(compared)Tj
4.2463 0 Td
(to)Tj
1.0261 0 Td
(non-)Tj
-34.8148 -1.2983 Td
(treated)Tj
2.9933 0 Td
(bacteria)Tj
3.3789 0 Td
(at)Tj
0.9524 0 Td
(10)Tj
/F17 1 Tf
1.1736 0 Td
()Tj
/F7 1 Tf
(M.)Tj
1.8481 0 Td
(Primary)Tj
3.4923 0 Td
(hits)Tj
1.6781 0 Td
(\(20)Tj
1.508 0 Td
(compounds\))Tj
5.3008 0 Td
(were)Tj
2.1203 0 Td
(tested)Tj
2.5568 0 Td
(in)Tj
1.0318 0 Td
(a)Tj
0.6577 0 Td
(secondary)Tj
4.2689 0 Td
(screen)Tj
-32.961 -1.2982 Td
(using)Tj
2.3867 0 Td
(the)Tj
1.4683 0 Td
(resazurin)Tj
3.9402 0 Td
(microtiter)Tj
4.2689 0 Td
(assay)Tj
2.2621 0 Td
(\(REMA\))Tj
3.668 0 Td
(at)Tj
0.9524 0 Td
(10)Tj
/F17 1 Tf
1.1735 0 Td
()Tj
/F7 1 Tf
(M)Tj
1.6214 0 Td
(on)Tj
1.2756 0 Td
(the)Tj
/F13 1 Tf
1.4684 0 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
1.3152 0 Td
(\r\r\r\r)Tj
/F7 1 Tf
3.8268 0 Td
(ATCC)Tj
2.8403 0 Td
(19977)Tj
2.5965 0 Td
(strain.)Tj
-35.0643 -1.2983 Td
(Secondary)Tj
4.3823 0 Td
(hits)Tj
1.6781 0 Td
(\(9)Tj
1.0318 0 Td
(compounds\))Tj
5.3007 0 Td
(were)Tj
2.126 0 Td
(then)Tj
2.0183 0 Td
(tested)Tj
2.5511 0 Td
(in)Tj
1.0318 0 Td
(a)Tj
0.6577 0 Td
(dose-response)Tj
5.9017 0 Td
(assay)Tj
2.262 0 Td
(on)Tj
/F13 1 Tf
1.2756 0 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
1.3209 0 Td
(\r\r\r\r)Tj
/F7 1 Tf
-31.538 -1.3039 Td
(ATCC)Tj
2.8402 0 Td
(19977)Tj
2.5966 0 Td
(from)Tj
2.2053 0 Td
(a)Tj
0.6576 0 Td
(fresh)Tj
2.1884 0 Td
(solid)Tj
2.1316 0 Td
(compound)Tj
4.5978 0 Td
(to)Tj
1.0261 0 Td
(determine)Tj
4.32 0 Td
(MIC)Tj
ET
Q
q
1 j
1 J
0.0001 w
7.4999 0 0 6.6659 444.642 432.34 cm
BT
/F7 1 Tf
-0.0053 Tc
1 TL
0 0 Td
(90)Tj
ET
Q
q
1 j
1 J
0.0001 w
10 0 0 10 451.729 433.984 cm
BT
/F7 1 Tf
-0.004 Tc
1 TL
0 0 Td
(.)Tj
0.4478 0 Td
(The)Tj
1.7802 0 Td
(HepG2)Tj
3.1237 0 Td
(\(human)Tj
3.4129 0 Td
(hepato-)Tj
-33.936 -1.2982 Td
(cytes\))Tj
2.5171 0 Td
(cell)Tj
1.5647 0 Td
(line)Tj
1.7008 0 Td
(was)Tj
1.7008 0 Td
(used)Tj
2.0579 0 Td
(to)Tj
1.0261 0 Td
(assess)Tj
2.5229 0 Td
(the)Tj
1.4683 0 Td
(toxicity)Tj
3.2031 0 Td
(of)Tj
1.0148 0 Td
(hits.)Tj
1.8992 0 Td
(Among)Tj
3.2428 0 Td
(three)Tj
2.2676 0 Td
(compounds)Tj
4.955 0 Td
(\(0.3%)Tj
2.4944 0 Td
(positive)Tj
-33.6355 -1.2983 Td
(hits)Tj
1.6724 0 Td
(of)Tj
1.0148 0 Td
(976)Tj
1.6497 0 Td
(compounds\))Tj
5.2951 0 Td
(from)Tj
2.2054 0 Td
(the)Tj
1.474 0 Td
(pandemic)Tj
4.1782 0 Td
(response)Tj
3.736 0 Td
(box)Tj
1.6952 0 Td
(that)Tj
1.7801 0 Td
(satisfied)Tj
3.4468 0 Td
(primary)Tj
3.4583 0 Td
(and)Tj
1.7291 0 Td
(secondary)Tj
-33.3351 -1.3039 Td
(criteria,)Tj
3.2995 0 Td
(we)Tj
1.3266 0 Td
(identified)Tj
4.0592 0 Td
(EPT)Tj
1.9615 0 Td
(\()Tj
0.83 0.64 0.02 0 k
(Fig)Tj
1.8198 0 Td
(1A)Tj
0 g
(\))Tj
1.7178 0 Td
(as)Tj
1.0148 0 Td
(having)Tj
2.9197 0 Td
(the)Tj
1.4683 0 Td
(most)Tj
2.2054 0 Td
(potent)Tj
2.8119 0 Td
(antimycobacterial)Tj
7.3813 0 Td
(activity)Tj
3.1181 0 Td
(and)Tj
-35.1039 -1.2983 Td
(highest)Tj
3.0897 0 Td
(therapeutic)Tj
4.7338 0 Td
(index)Tj
2.4491 0 Td
(\()Tj
0.83 0.64 0.02 0 k
(Table)Tj
2.7837 0 Td
(1)Tj
0 g
(,)Tj
0.9184 0 Td
(MIC)Tj
ET
Q
q
1 j
1 J
0.0001 w
7.4999 0 0 6.6659 358.753 380.353 cm
BT
/F7 1 Tf
-0.0053 Tc
1 TL
0 0 Td
(90)Tj
ET
Q
q
1 j
1 J
0.0001 w
10 0 0 10 368.05 381.997 cm
BT
/F7 1 Tf
-0.004 Tc
1 TL
0 0 Td
(0.23)Tj
/F17 1 Tf
1.8708 0 Td
()Tj
/F7 1 Tf
(M)Tj
1.6214 0 Td
(\(0.063)Tj
/F17 1 Tf
2.6872 0 Td
()Tj
/F7 1 Tf
(g/mL\),)Tj
3.4469 0 Td
(TI)Tj
1.1736 0 Td
(\(TD)Tj
ET
Q
q
1 j
1 J
0.0001 w
7.4999 0 0 6.6659 492.888 380.353 cm
BT
/F7 1 Tf
-0.0053 Tc
1 TL
0 0 Td
(50)Tj
ET
Q
q
1 j
1 J
0.0001 w
10 0 0 10 500.031 381.997 cm
BT
/F7 1 Tf
-0.004 Tc
1 TL
0 0 Td
(/MIC)Tj
ET
Q
q
1 j
1 J
0.0001 w
7.4999 0 0 6.6659 522.312 380.353 cm
BT
/F7 1 Tf
-0.0053 Tc
1 TL
0 0 Td
(90)Tj
ET
Q
q
1 j
1 J
0.0001 w
10 0 0 10 529.398 381.997 cm
BT
/F7 1 Tf
-0.004 Tc
1 TL
0 0 Td
(\))Tj
-32.9383 -1.2982 Td
(EPT)Tj
/F18 1 Tf
0 Tc
1.9559 0 Td
(>)Tj
/F7 1 Tf
-0.004 Tc
0.9921 0 Td
(330\).)Tj
2.2167 0 Td
(It)Tj
0.856 0 Td
(was)Tj
1.7008 0 Td
(previously)Tj
4.3483 0 Td
(reported)Tj
3.6624 0 Td
(in)Tj
/F13 1 Tf
1.0318 0 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
1.3209 0 Td
( \r\n\r)Tj
/F7 1 Tf
4.8415 0 Td
(that)Tj
1.7802 0 Td
(potent)Tj
/F13 1 Tf
2.8119 0 Td
(\n)Tj
1.0148 0 Td
(\n )Tj
/F7 1 Tf
2.0636 0 Td
(growth)Tj
3.0784 0 Td
(inhibitors)Tj
-33.6753 -1.3039 Td
(could)Tj
2.4491 0 Td
(display)Tj
3.0274 0 Td
(carbon-source-dep)Tj
7.5798 0 Td
(endent)Tj
2.9877 0 Td
(effects,)Tj
2.9537 0 Td
(which)Tj
2.6475 0 Td
(leads)Tj
2.211 0 Td
(to)Tj
1.0261 0 Td
(a)Tj
0.652 0 Td
(loss)Tj
1.6951 0 Td
(of)Tj
1.0148 0 Td
(activity)Tj
3.1181 0 Td
(when)Tj
2.4037 0 Td
(advanced)Tj
-33.766 -1.2983 Td
(into)Tj
/F13 1 Tf
1.8425 0 Td
(\n)Tj
1.0148 0 Td
(\n)Tj
/F7 1 Tf
1.8425 0 Td
(models)Tj
3.1011 0 Td
([)Tj
0.83 0.64 0.02 0 k
(16)Tj
0 g
(].)Tj
2.0806 0 Td
(We)Tj
1.6044 0 Td
(thus)Tj
1.9389 0 Td
(measured)Tj
4.1045 0 Td
(the)Tj
1.474 0 Td
(MIC)Tj
ET
Q
q
1 j
1 J
0.0001 w
7.4999 0 0 6.6659 408.983 341.348 cm
BT
/F7 1 Tf
-0.0053 Tc
1 TL
0 0 Td
(90)Tj
ET
Q
q
1 j
1 J
0.0001 w
10 0 0 10 418.28 342.992 cm
BT
/F7 1 Tf
-0.004 Tc
1 TL
0 0 Td
(of)Tj
1.0147 0 Td
(EPT)Tj
1.9616 0 Td
(on)Tj
1.2756 0 Td
(different)Tj
3.6567 0 Td
(carbon)Tj
3.0103 0 Td
(sources)Tj
-32.7455 -1.2982 Td
(\(glycerol)Tj
3.6964 0 Td
(vs)Tj
1.0374 0 Td
(acetate\),)Tj
3.5207 0 Td
(in)Tj
1.0318 0 Td
(the)Tj
1.474 0 Td
(presence)Tj
3.7077 0 Td
(or)Tj
1.0998 0 Td
(absence)Tj
3.3392 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.474 0 Td
(detergent)Tj
3.9967 0 Td
(Tween-80,)Tj
4.439 0 Td
(and)Tj
1.7292 0 Td
(in)Tj
1.0374 0 Td
(different)Tj
-32.5981 -1.2983 Td
(nutrient)Tj
3.5036 0 Td
(bases)Tj
2.3074 0 Td
(\(Middlebrook)Tj
5.8337 0 Td
(7H9)Tj
1.9389 0 Td
(vs)Tj
1.0318 0 Td
(cation-adjusted)Tj
6.4062 0 Td
(Mueller-Hinton\).)Tj
7.2055 0 Td
(EPT)Tj
1.9616 0 Td
(was)Tj
1.6951 0 Td
(active)Tj
2.5228 0 Td
(in)Tj
1.0375 0 Td
(all)Tj
-35.4441 -1.3039 Td
(assayed)Tj
3.2145 0 Td
(growth)Tj
3.0727 0 Td
(conditions)Tj
4.4787 0 Td
(but)Tj
1.5534 0 Td
(lost)Tj
1.6328 0 Td
(potency)Tj
3.3902 0 Td
(in)Tj
1.0374 0 Td
(cation-adjusted)Tj
6.4062 0 Td
(Mueller)Tj
3.3505 0 Td
(Hinton)Tj
3.1578 0 Td
(\(CaMH\))Tj
3.6567 0 Td
(media)Tj
-34.9509 -1.2983 Td
(\()Tj
0.83 0.64 0.02 0 k
(S1)Tj
1.508 0 Td
(Table)Tj
0 g
(\).)Tj
3.0104 0 Td
(Lower)Tj
2.7439 0 Td
(activity)Tj
3.1181 0 Td
(of)Tj
1.0148 0 Td
(EPT)Tj
1.9559 0 Td
(in)Tj
1.0375 0 Td
(CaMH)Tj
2.9763 0 Td
(media)Tj
2.6929 0 Td
(is)Tj
0.8504 0 Td
(unsurprising)Tj
5.3517 0 Td
(as)Tj
1.0148 0 Td
(it)Tj
0.788 0 Td
(was)Tj
1.6951 0 Td
(previously)Tj
4.354 0 Td
(shown)Tj
-34.1118 -1.2982 Td
(that)Tj
1.7745 0 Td
(rifamycins)Tj
4.456 0 Td
([)Tj
0.83 0.64 0.02 0 k
(17)Tj
0 g
(])Tj
1.8539 0 Td
(as)Tj
1.0148 0 Td
(well)Tj
1.8198 0 Td
(as)Tj
1.0148 0 Td
(other)Tj
2.3471 0 Td
(antimicrobials)Tj
5.9697 0 Td
([)Tj
0.83 0.64 0.02 0 k
(18)Tj
0 g
(])Tj
1.8537 0 Td
(lose)Tj
1.7575 0 Td
(activity)Tj
3.1181 0 Td
(in)Tj
1.0375 0 Td
(CaMH)Tj
2.9763 0 Td
(media)Tj
2.6929 0 Td
(\(0.5mg/L)Tj
-33.6866 -1.3039 Td
(Ca)Tj
ET
Q
q
1 j
1 J
0.0001 w
7.4999 0 0 6.6659 210.954 269.461 cm
BT
/F7 1 Tf
-0.0053 Tc
1 TL
0 0 Td
(2+)Tj
ET
Q
q
1 j
1 J
0.0001 w
10 0 0 10 221.046 264.983 cm
BT
/F7 1 Tf
-0.004 Tc
1 TL
0 0 Td
(and)Tj
1.7347 0 Td
(0.05mg/L)Tj
4.0252 0 Td
(Mg)Tj
ET
Q
q
1 j
1 J
0.0001 w
7.4999 0 0 6.6659 292.195 269.461 cm
BT
/F7 1 Tf
-0.0053 Tc
1 TL
0 0 Td
(2+)Tj
ET
Q
q
1 j
1 J
0.0001 w
10 0 0 10 302.287 264.983 cm
BT
/F7 1 Tf
-0.004 Tc
1 TL
0 0 Td
(in)Tj
1.0374 0 Td
(7H9;)Tj
2.1657 0 Td
(20-25mg/L)Tj
4.6261 0 Td
(Ca)Tj
ET
Q
q
1 j
1 J
0.0001 w
7.4999 0 0 6.6659 391.521 269.461 cm
BT
/F7 1 Tf
-0.0053 Tc
1 TL
0 0 Td
(2+)Tj
ET
Q
q
1 j
1 J
0.0001 w
10 0 0 10 401.613 264.983 cm
BT
/F7 1 Tf
-0.004 Tc
1 TL
0 0 Td
(and)Tj
1.7291 0 Td
(1012.5mg/L)Tj
5.4935 0 Td
(Mg)Tj
ET
Q
q
1 j
1 J
0.0001 w
7.4999 0 0 6.6659 487.446 269.461 cm
BT
/F7 1 Tf
-0.0053 Tc
1 TL
0 0 Td
(2+)Tj
ET
Q
q
1 j
1 J
0.0001 w
10 0 0 10 497.537 264.983 cm
BT
/F7 1 Tf
-0.004 Tc
1 TL
0 0 Td
(in)Tj
1.0374 0 Td
(CaMH\).)Tj
3.5433 0 Td
(It)Tj
0.8561 0 Td
(is)Tj
-35.189 -1.2982 Td
(thought)Tj
3.3732 0 Td
(that)Tj
1.7745 0 Td
(some)Tj
2.33 0 Td
(antimicrobials)Tj
5.9754 0 Td
(may)Tj
1.9276 0 Td
(chelate)Tj
2.999 0 Td
(divalent)Tj
3.4186 0 Td
(metal)Tj
2.4378 0 Td
(ions,)Tj
2.1316 0 Td
(thus)Tj
1.9332 0 Td
(limiting)Tj
3.4015 0 Td
(their)Tj
2.1089 0 Td
(uptake)Tj
2.914 0 Td
(in)Tj
-36.7253 -1.2983 Td
(cells.)Tj
1.1962 -1.3039 Td
(Next,)Tj
2.3698 0 Td
(we)Tj
1.3266 0 Td
(tested)Tj
2.5568 0 Td
(the)Tj
/F13 1 Tf
1.4683 0 Td
(\n)Tj
1.0148 0 Td
(\n )Tj
/F7 1 Tf
2.0636 0 Td
(activity)Tj
3.1181 0 Td
(of)Tj
1.0148 0 Td
(EPT)Tj
1.9616 0 Td
(against)Tj
3.0274 0 Td
(a)Tj
0.6519 0 Td
(panel)Tj
2.3925 0 Td
(of)Tj
/F13 1 Tf
1.0148 0 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
1.3152 0 Td
(\r\r\r\r)Tj
/F7 1 Tf
3.821 0 Td
(clinical)Tj
3.0784 0 Td
(isolates)Tj
-33.3918 -1.2983 Td
(belonging)Tj
4.1952 0 Td
(to)Tj
1.0262 0 Td
(the)Tj
1.4683 0 Td
(three)Tj
2.2677 0 Td
(subspecies)Tj
4.3937 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
/F13 1 Tf
1.4683 0 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
1.3153 0 Td
(\r\r\r\r)Tj
/F7 1 Tf
3.8267 0 Td
(complex)Tj
3.617 0 Td
(\()Tj
/F13 1 Tf
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
1.6611 0 Td
(\r\r\r\r)Tj
/F7 1 Tf
(,)Tj
/F13 1 Tf
4.0478 0 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
1.3152 0 Td
(\r\r\n\n\r)Tj
/F7 1 Tf
(,)Tj
-31.6173 -1.2982 Td
(and)Tj
/F13 1 Tf
1.7291 0 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
1.3153 0 Td
(\n\n)Tj
/F7 1 Tf
(\))Tj
3.2371 0 Td
(with)Tj
1.9956 0 Td
(smooth)Tj
3.2428 0 Td
(and)Tj
1.7291 0 Td
(rough)Tj
2.6192 0 Td
(colony)Tj
2.9084 0 Td
(morphologies)Tj
5.7373 0 Td
(and)Tj
1.7291 0 Td
(with)Tj
2.0012 0 Td
(different)Tj
3.6566 0 Td
(drug)Tj
2.109 0 Td
(suscepti-)Tj
-34.0098 -1.3039 Td
(bility)Tj
2.2564 0 Td
(profiles)Tj
3.2031 0 Td
(to)Tj
1.0261 0 Td
(various)Tj
3.1408 0 Td
(antibiotics.)Tj
4.6261 0 Td
(There)Tj
2.5795 0 Td
(was)Tj
1.6951 0 Td
(no)Tj
1.2756 0 Td
(loss)Tj
1.6951 0 Td
(in)Tj
1.0375 0 Td
(activity)Tj
3.1181 0 Td
(against)Tj
3.0274 0 Td
(clinical)Tj
3.0783 0 Td
(isolates)Tj
3.1181 0 Td
(\(range)Tj
-34.8772 -1.2983 Td
(of)Tj
1.0148 0 Td
(0.0140.046)Tj
/F17 1 Tf
4.9946 0 Td
()Tj
/F7 1 Tf
(g/mL\))Tj
3.2201 0 Td
(nor)Tj
1.6441 0 Td
(different)Tj
3.6567 0 Td
(morphologies)Tj
5.7373 0 Td
(\()Tj
0.83 0.64 0.02 0 k
(S2)Tj
1.5137 0 Td
(Table)Tj
0 g
(\).)Tj
3.0047 0 Td
(To)Tj
1.3379 0 Td
(determine)Tj
4.3256 0 Td
(the)Tj
1.4683 0 Td
(spectrum)Tj
3.9628 0 Td
(of)Tj
-35.8806 -1.2983 Td
(activity)Tj
3.1181 0 Td
(of)Tj
1.0148 0 Td
(EPT,)Tj
2.1826 0 Td
(we)Tj
1.3267 0 Td
(curated)Tj
3.2258 0 Td
(a)Tj
0.6576 0 Td
(panel)Tj
2.3867 0 Td
(of)Tj
1.0148 0 Td
(various)Tj
3.1465 0 Td
(mycobacteria)Tj
5.5785 0 Td
(and)Tj
1.7348 0 Td
(representative)Tj
5.8336 0 Td
(gram-positive)Tj
-31.2205 -1.2982 Td
(and)Tj
1.7291 0 Td
(gram-negative)Tj
5.9754 0 Td
(bacteria.)Tj
3.6057 0 Td
(Interestingly,)Tj
5.4878 0 Td
(EPT)Tj
1.9616 0 Td
(appears)Tj
3.2768 0 Td
(to)Tj
1.0261 0 Td
(be)Tj
1.1509 0 Td
(more)Tj
2.3414 0 Td
(selective)Tj
3.5432 0 Td
(for)Tj
/F13 1 Tf
1.3833 0 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
1.3209 0 Td
(\r\r\r\r)Tj
/F7 1 Tf
-32.8022 -1.304 Td
(with)Tj
1.9956 0 Td
(lower)Tj
2.4548 0 Td
(activity)Tj
3.1181 0 Td
(against)Tj
/F13 1 Tf
3.0273 0 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
1.3153 0 Td
( \r\n\r)Tj
/F7 1 Tf
4.8472 0 Td
(H37Rv)Tj
3.0161 0 Td
(\()Tj
0.83 0.64 0.02 0 k
(S3)Tj
1.508 0 Td
(Table)Tj
0 g
(\).)Tj
/F13 1 Tf
3.0104 0 Td
()Tj
1.0771 0 Td
(\n )Tj
/F7 1 Tf
2.0636 0 Td
(growth)Tj
3.0727 0 Td
(kill)Tj
1.474 0 Td
(kinetics)Tj
3.3051 0 Td
(indi-)Tj
-35.2853 -1.2982 Td
(cated)Tj
2.3244 0 Td
(that)Tj
1.7801 0 Td
(EPT)Tj
1.9616 0 Td
(is)Tj
0.8447 0 Td
(bacteriostatic)Tj
5.5332 0 Td
(against)Tj
/F13 1 Tf
3.0274 0 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
1.3209 0 Td
(\r\r\r\r)Tj
/F7 1 Tf
3.8211 0 Td
(as)Tj
1.0148 0 Td
(previously)Tj
4.354 0 Td
(demonstrated)Tj
5.7599 0 Td
(against)Tj
/F13 1 Tf
3.0273 0 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
-34.7694 -1.2983 Td
( \r\n\r)Tj
/F7 1 Tf
4.8415 0 Td
([)Tj
0.83 0.64 0.02 0 k
(19)Tj
0 g
(],)Tj
2.0807 0 Td
(while)Tj
2.3697 0 Td
(10%)Tj
1.9276 0 Td
(of)Tj
1.0148 0 Td
(CFUs)Tj
2.5058 0 Td
(were)Tj
2.1203 0 Td
(lost)Tj
1.6327 0 Td
(at)Tj
0.9524 0 Td
(24)Tj
1.1736 0 Td
(hours)Tj
2.5171 0 Td
(with)Tj
1.9956 0 Td
(AMK)Tj
2.4718 0 Td
(and)Tj
1.7291 0 Td
(rifampicin)Tj
4.4219 0 Td
(\(RIF\))Tj
2.3925 0 Td
(at)Tj
-36.1471 -1.3039 Td
(20X)Tj
1.8255 0 Td
(MIC)Tj
ET
Q
q
1 j
1 J
0.0001 w
7.4999 0 0 6.6659 237.203 94.337 cm
BT
/F7 1 Tf
-0.0053 Tc
1 TL
0 0 Td
(90)Tj
ET
Q
q
1 j
1 J
0.0001 w
10 0 0 10 244.29 95.9811 cm
BT
/F7 1 Tf
-0.004 Tc
1 TL
0 0 Td
(.)Tj
0.4478 0 Td
(Interestingly,)Tj
5.4935 0 Td
(these)Tj
2.2507 0 Td
(two)Tj
1.7121 0 Td
(antimycobacterial)Tj
7.3757 0 Td
(agents)Tj
2.7496 0 Td
(with)Tj
2.0013 0 Td
(bactericidal)Tj
4.8415 0 Td
(action)Tj
2.6986 0 Td
(against)Tj
-33.9984 -1.2982 Td
(other)Tj
2.347 0 Td
(mycobacteria)Tj
5.5841 0 Td
(lose)Tj
1.7575 0 Td
(this)Tj
1.6724 0 Td
(ability)Tj
2.6929 0 Td
(when)Tj
2.4038 0 Td
(targeting)Tj
/F13 1 Tf
3.7927 0 Td
()Tj
/F7 1 Tf
(.)Tj
/F13 1 Tf
1.321 0 Td
(\r\r\r\r)Tj
/F7 1 Tf
3.8211 0 Td
(\()Tj
0.83 0.64 0.02 0 k
(Fig)Tj
1.8198 0 Td
(1B)Tj
0 g
(\))Tj
1.6157 0 Td
([)Tj
0.83 0.64 0.02 0 k
(20)Tj
0 g
(].)Tj
ET
Q
q
1 j
1 J
0.0001 w
576 737.1 m
36 737.1 l
36 737.6 l
576 737.6 l
f*
Q
q
34.9795 742.734 100.29 12.3591 re
W* n
q
1 0 0 1 34.9795 742.734 cm
q
/I5 Do
Q
Q
Q
q
0 0 612 792 re
W* n
1 j
1 J
0.0001 w
7.9999 0 0 7.9999 420.831 745.795 cm
BT
/F0 1 Tf
-0.005 Tc
1 TL
0 0 Td
(Epetrabor)Tj
4.3157 0 Td
(ole)Tj
1.5237 0 Td
(plus)Tj
2.0197 0 Td
(norvaline)Tj
4.1953 0 Td
(for)Tj
/F6 1 Tf
1.3677 0 Td
(M)Tj
/F0 1 Tf
(.)Tj
/F6 1 Tf
1.3181 0 Td
(abscessus)Tj
ET
Q
q
1 j
1 J
0.0001 w
36 48.0002 m
576 48.0002 l
576 47.5002 l
36 47.5002 l
f*
0.83 0.64 0.02 0 k
102.047 34.9228 m
256.195 34.9228 l
h
f*
0 g
7.9999 0 0 7.9999 36 36 cm
BT
/F0 1 Tf
-0.005 Tc
1 TL
0 0 Td
(PLOS)Tj
2.8559 0 Td
(Pathogens)Tj
4.9252 0 Td
(|)Tj
0.83 0.64 0.02 0 k
0.4748 0 Td
(https://)Tj
2.9552 0 Td
(doi.org/10.13)Tj
5.7331 0 Td
(71/journal.p)Tj
5.1236 0 Td
(pat.1009)Tj
3.8198 0 Td
(965)Tj
0 g
2.6362 0 Td
(October)Tj
3.7276 0 Td
(12,)Tj
1.5874 0 Td
(2021)Tj
31.3018 0 Td
(3)Tj
0.7654 0 Td
(/)Tj
0.496 0 Td
(28)Tj
ET
Q
endstream
endobj
62 0 obj
<>
endobj
64 0 obj
<>/ProcSet 14 0 R/XObject<>>>
endobj
66 0 obj
<>stream
xyMHdHh 4$(44OK$
"[4PP4(n*+3)93<kX{Zk_~G}ԯ_.]֭ܳke˖p EG=D
gG?Q D`ʔ)qm%@ D6m:rDvuO?^Hb
@=+V\zuB $e*Wk%/8"@ P0kQF^1c,9! @ @ ,]4K^mNpH ѣ(.*@ZB <5k˷zp ׯVZx_|1#@ +;*9ro @ H<6&M믃
i9B5d@ Ppi=pSL*U9bŊyCa D4l0W_}xaf^reNMB @ @ 6,4h>PBتU! @ @^b(!ji
y%K8 @ H&֭[kVG6,]Y* @ &ӬYLK,'enA PDboy0PS$r @ $MvaFKlٲQ @ &K/}?Pf*QDxSNItaH H M樣W,E;! @ di
/pɊY$5/!9B rd5ji2p˖-vuzP
tTƌ%ׯ_؇ܽ{w @ @Nᶒh瞋A! @ Qhu^-\2_;cpGё! @ @Qi ;-9O?}ժUEUZ @ '|rc#
}
op @ O6wq͛_Zr @ !9s)S&ɄLSNB=zA @ EB64o|ƍERf2 @ FO>9֮]?,Y2T;C":\B iQgF,
4hC}ڶm[N'c7ߜ# @ puIBᬳ
{2Zg
@ rd7n+VΌɟ~iNeB @ @|wŋ'_6{W&SNI(!Y@ |4l0/}St%/e! @ @B s=I엵j?Z< @ (M'tu.. @ H-[ԫW/3)ĉQ0҄ @ 1(MfرN6mb5@ G_};Kql @
d6lX#yȔ( @`; u]aD;+i_en
7p9Ujժ,! @ @ &sꩧF:3lThD @pay~=3"yȑ. @ H6\]R:trɉ+)C \ 7.-{ssvf.P $@NL͚5
4cwqG&M"=]jL2J^ @xaϤXb63&%RJ,_&7 @ H6H_%*U̚5+A"Y@ Bw}.J)/}߸q{F/ @ H&K^6/<1$/@ `^}H_;_{5@ _T nΌfķ@ b$vRJ͘1#ƸǏJަsSF
@~ʕ+W&Cvc=ꫯ~gΝ[,@ E@`o߾?ӦM+PΏ,y?S@ K`ɒ%>4+f˖-͑ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ d<_^uܼys^ @ @ (4iӦtI^xe"ݻy}s @ @ =~
;00ѣG+\g#C @ lSzfxZ
-M6=J[^zB\@ @ aL[o;g6n駟7N
+W(